
Opinion|Videos|December 9, 2025
Exploring Percutaneous Hepatic Perfusion in Metastatic Uveal Melanoma
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss the use of percutaneous hepatic perfusion in metastatic uveal melanoma.
Advertisement
Episodes in this series

Prof.Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss the rationale behind percutaneous hepatic perfusion (PHP) as a regional therapy designed to control liver-dominant disease in patients with metastatic uveal melanoma. They outline how PHP delivers high-dose chemotherapy directly to the liver with systemic exposure mitigation, offering a potential therapeutic advantage for selected patients. They also comment on procedural considerations and evolving clinical data that support its use.
Advertisement
Related to this article

The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.

The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.

The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.

Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.

Surgeons at the UC San Francisco have performed over 25,000 robotically assisted minimally invasive surgeries.

Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 10/4/2026
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
4
FDA Flashback: Hematologic Cancer Decisions and News From September 2026
5


